Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Delafloxacin showed no significant difference in clinical cure rate compared to other antibiotics for treating acute bacterial infections in adults, with an odds ratio (OR) of 1.06 (95% CI (confidence interval): 0.89-1.26). Its microbiological eradication rate was also similar to comparators (OR: 1.33, 95% CI: 0.94-1.88).
• For acute bacterial skin and skin structure infections (ABSSSI), delafloxacin was non-inferior to tigecycline and linezolid, and superior to vancomycin in terms of pooled cure rates, with a pooled efficacy of 80% (95% CI: 1.01 [0.97-1.06]).
• Delafloxacin demonstrated a safety profile similar to comparator antibiotics, with no significant differences in treatment-emergent adverse events (OR = 0.93%, 95% CI = 0.80-1.08) or serious adverse events (OR = 0.94%, 95% CI = 0.67-1.32).
• Delafloxacin had a higher incidence of diarrhea (OR = 2.10%, 95% CI = 1.70-2.96) compared to comparators but a lower incidence of nervous system disorders (OR = 0.71%, 95% CI = 0.50-1.01).
• There is no population types or subgroups information available in the reviewed studies.